Drugs Made In America Acquisition (DMAA) Competitors $10.26 -0.03 (-0.29%) As of 09/5/2025 03:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOwnershipSEC FilingsTrendsBuy This Stock DMAA vs. BRDG, SAFE, SBR, DEA, UNIT, PLYM, CSR, FBRT, PAX, and ORCShould you be buying Drugs Made In America Acquisition stock or one of its competitors? The main competitors of Drugs Made In America Acquisition include Bridge Investment Group (BRDG), Safehold (SAFE), Sabine Royalty Trust (SBR), Easterly Government Properties (DEA), Uniti Group (UNIT), Plymouth Industrial REIT (PLYM), Centerspace (CSR), Franklin BSP Realty Trust (FBRT), Patria Investments (PAX), and Orchid Island Capital (ORC). These companies are all part of the "trading" industry. Drugs Made In America Acquisition vs. Its Competitors Bridge Investment Group Safehold Sabine Royalty Trust Easterly Government Properties Uniti Group Plymouth Industrial REIT Centerspace Franklin BSP Realty Trust Patria Investments Orchid Island Capital Bridge Investment Group (NYSE:BRDG) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability. Do analysts prefer BRDG or DMAA? Bridge Investment Group currently has a consensus price target of $10.70, indicating a potential upside of 13.11%. Given Bridge Investment Group's stronger consensus rating and higher probable upside, analysts plainly believe Bridge Investment Group is more favorable than Drugs Made In America Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bridge Investment Group 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Drugs Made In America Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to BRDG or DMAA? In the previous week, Bridge Investment Group had 6 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 6 mentions for Bridge Investment Group and 0 mentions for Drugs Made In America Acquisition. Bridge Investment Group's average media sentiment score of 0.85 beat Drugs Made In America Acquisition's score of 0.00 indicating that Bridge Investment Group is being referred to more favorably in the media. Company Overall Sentiment Bridge Investment Group Positive Drugs Made In America Acquisition Neutral Is BRDG or DMAA more profitable? Drugs Made In America Acquisition has a net margin of 0.00% compared to Bridge Investment Group's net margin of -3.03%. Bridge Investment Group's return on equity of 8.42% beat Drugs Made In America Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Bridge Investment Group-3.03% 8.42% 3.36% Drugs Made In America Acquisition N/A N/A N/A Do institutionals and insiders hold more shares of BRDG or DMAA? 52.8% of Bridge Investment Group shares are held by institutional investors. 65.9% of Bridge Investment Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, BRDG or DMAA? Bridge Investment Group has higher revenue and earnings than Drugs Made In America Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridge Investment Group$397.73M2.96$8.01M-$0.42-22.52Drugs Made In America AcquisitionN/AN/AN/AN/AN/A SummaryBridge Investment Group beats Drugs Made In America Acquisition on 9 of the 10 factors compared between the two stocks. Get Drugs Made In America Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAA vs. The Competition Export to ExcelMetricDrugs Made In America AcquisitionInvestment Offices IndustryFinancial SectorNASDAQ ExchangeMarket Cap$299.29M$193.85M$6.27B$9.91BDividend YieldN/AN/A4.32%4.53%P/E RatioN/AN/A1,762.9626.13Price / SalesN/AN/A1,359.5182.09Price / CashN/A36,966.89127.5159.04Price / BookN/AN/A2.056.09Net IncomeN/A-$160K$1.23B$266.51M7 Day Performance0.10%0.00%-0.20%0.45%1 Month Performance-0.10%-0.15%1.75%4.58%1 Year PerformanceN/A7.40%27.02%26.03% Drugs Made In America Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMAADrugs Made In America AcquisitionN/A$10.26-0.3%N/AN/A$299.29MN/A0.002BRDGBridge Investment Group3.149 of 5 stars$9.66+0.5%$10.70+10.8%+17.2%$1.20B$412.43M17.162,250News CoveragePositive NewsShort Interest ↑SAFESafehold3.898 of 5 stars$16.07-0.3%$21.89+36.3%-34.7%$1.16B$365.68M11.23120Positive NewsSBRSabine Royalty Trust2.0309 of 5 stars$73.74+2.0%N/A+20.6%$1.05B$83.17M14.352,020News CoverageDividend AnnouncementDEAEasterly Government Properties3.3196 of 5 stars$22.84-1.1%$27.15+18.9%-31.0%$1.05B$302.05M55.7150UNITUniti Group2.6438 of 5 stars$6.59-0.6%$6.70+1.7%+22.0%$981.13M$1.17B24.10750News CoveragePositive NewsGap UpPLYMPlymouth Industrial REIT3.5993 of 5 stars$21.99+0.3%$20.67-6.0%-3.2%$976.62M$198.35M12.1840Positive NewsCSRCenterspace2.9383 of 5 stars$58.66+0.8%$68.75+17.2%-19.6%$975.24M$260.98M11.93470Dividend AnnouncementShort Interest ↑FBRTFranklin BSP Realty Trust4.4897 of 5 stars$11.350.0%$14.88+31.1%-11.6%$933.82M$210.45M16.69N/APositive NewsPAXPatria Investments2.9864 of 5 stars$13.47+0.4%$14.00+3.9%+24.9%$896.05M$397.50M26.94390News CoveragePositive NewsAnalyst UpgradeORCOrchid Island Capital3.4538 of 5 stars$7.08+0.4%N/A-11.8%$893.44M$241.58M22.032,018Positive News Related Companies and Tools Related Companies BRDG Alternatives SAFE Alternatives SBR Alternatives DEA Alternatives UNIT Alternatives PLYM Alternatives CSR Alternatives FBRT Alternatives PAX Alternatives ORC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAA) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Drugs Made In America Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Drugs Made In America Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
